Abstract #1999
Prediction of Treatment Response in Pancreatic Cancer Using EPR Oxygen Imaging
Shingo Matsumoto 1,2 , Keita Saito 1 , Jeeva P Munasinghe 3 , Nallathamby Devasahayam 1 , James B Mitchell 1 , Robert J Gillies 4 , and Murali C Krishna 1
1
Radiation Biology Branch, National Cancer
Institute, NIH, Bethesda, MD, United States,
2
Hokkaido
University, Sapporo, Hokkaido, Japan,
3
Mouse
Imaging Facility, NINDS, NIH, Bethesda, MD, United
States,
4
Imaging
and Metabolism, H. Lee Moffitt Cancer Center and
Research Institute, Tampa, FL, United States
Pancreatic cancer is a malignant neoplasm with an
extremely poor prognosis. The TH-302 is a kind of drugs
known as hypoxia-activated prodrug (HAP), which
activated under hypoxia (low concentration of oxygen)
and exhibits anti-tumor effect. A question derived is
how clinicians select patients who receive most benefit
from treatment with this hypoxia targeting new drug.
Electron paramagnetic resonance imaging (EPRI) can
non-invasively provide 3D absolute oxygen images. Here,
we investigated if the EPR oxygen imaging can predict
treatment benefit of oxygen dependent or independent
therapies in three different pancreatic cancer
xenografts.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
